Want to see PRFX full AI Analyst Report?
Top Page
PainReform
(NASDAQ:PRFX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.85
▼(-14.65% Downside)
Action:Reiterated
Date:09/17/26
PRFX scores low primarily due to very weak financial performance: minimal revenue scale paired with large operating/net losses and substantial ongoing cash burn. Technicals also lean bearish given the stock trading below key longer-term moving averages and a negative MACD, while valuation provides little support because earnings are negative and no dividend yield is indicated.
Positive Factors
Low Leverage
Minimal debt relative to equity keeps borrowing-related risk low and preserves flexibility for clinical development and commercialization spending. This is a durable balance-sheet advantage, although it does not offset the company’s current operating losses or funding needs.
Negative Factors
Minimal Revenue Scale
The extremely small revenue base relative to operating and net losses shows that commercialization has not yet produced meaningful economic scale. Until revenue expands substantially, fixed development expenses will continue to dominate results and limit the path toward profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt relative to equity keeps borrowing-related risk low and preserves flexibility for clinical development and commercialization spending. This is a durable balance-sheet advantage, although it does not offset the company’s current operating losses or funding needs.
Read all positive factors
PainReform (PRFX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.68M
Dividend YieldN/A
Average Volume (3M)286.06K
Price to Earnings (P/E)―
Beta (1Y)2.17
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-11.16
Shares Outstanding3,041,830
10 Day Avg. Volume58,247
30 Day Avg. Volume286,057
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)122.35
P/FCF Ratio-0.53
Enterprise Value/Market Cap-3.43
Enterprise Value/Revenue-232.72
Enterprise Value/Gross Profit75.66
Enterprise Value/Ebitda1.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-176.4
Revenue Forecast (FY)$10.31M
PainReform Business Overview & Revenue Model
Company Description
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a ...
PainReform Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.50K | 17.00K | 0.00 | 0.00 | 86.00K | 0.00 |
| Gross Profit | -121.50K | -827.00K | -16.00K | -15.00K | 71.00K | ― |
| EBITDA | -7.39M | -4.21M | -14.55M | -9.57M | -8.76M | -7.22M |
| Net Income | -8.90M | -4.84M | -14.59M | -9.34M | -8.79M | -7.25M |
Balance Sheet | ||||||
| Total Assets | 19.09M | 12.00M | 4.53M | 9.93M | 12.33M | 19.07M |
| Cash, Cash Equivalents and Short-Term Investments | 11.54M | 4.17M | 4.26M | 8.03M | 4.10M | 16.54M |
| Total Debt | 50.00K | 21.00K | 45.00K | 86.00K | 0.00 | 0.00 |
| Total Liabilities | 2.62M | 2.71M | 2.70M | 2.69M | 1.31M | 991.00K |
| Stockholders Equity | 15.87M | 8.54M | 1.82M | 7.24M | 11.02M | 18.08M |
Cash Flow | ||||||
| Free Cash Flow | -7.38M | -3.96M | -12.63M | -6.69M | -6.46M | -6.60M |
| Operating Cash Flow | -7.38M | -3.96M | -12.62M | -6.68M | -6.46M | -6.55M |
| Investing Cash Flow | -3.45M | -982.00K | -13.00K | 5.99M | -6.01M | -50.00K |
| Financing Cash Flow | 14.93M | 3.82M | 8.86M | 4.62M | 0.00 | 7.48M |
PainReform Technical Analysis
Negative
0.99
Price Trends
0.98
Negative
1.24
Negative
2.10
Negative
Market Momentum
-0.03
Positive
38.54
Neutral
4.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRFX, the sentiment is Negative. The current price of 0.99 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.98, and below the 200-day MA of 2.10, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.54 is Neutral, neither overbought nor oversold. The STOCH value of 4.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRFX.
PainReform Risk Analysis
PainReform disclosed 46 risk factors in its most recent earnings report. PainReform reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PainReform Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $27.58M | -0.84 | -17.14% | ― | -10.97% | 71.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $32.15M | -0.49 | -118.89% | ― | 33.82% | 34.05% | |
42 Neutral | $2.68M | -0.08 | -72.87% | ― | ― | ― | |
41 Neutral | $2.94M | -3.49 | 206.75% | ― | ― | ― | |
32 Underperform | $19.34M | -0.15 | -156.78% | ― | ― | 94.90% |
* Healthcare Sector Average
PRFX
PainReform
0.88
-6.52
-88.15%
CPHI
China Pharma Holdings
0.85
-1.14
-57.29%
RDHL
RedHill Biopharma
0.47
-1.35
-73.96%
COSM
Cosmos Holdings
0.32
-0.74
-69.81%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
4.71
-39.19
-89.27%
PainReform Corporate Events
PRF Technologies Faces Board Shake-Up Bid from 5.7% Shareholder S.H.N.
Sep 28, 2026
On September 24, 2026, PRF Technologies Ltd. received a letter from S.H.N. Financial Investments Ltd., which claims to hold about 5.7% of the company’s voting rights, calling for a special general meeting to remove all directors other than t...
PRF Technologies Targets AI Data Centers With GridFeed Power Optimization Push
Sep 16, 2026
On September 16, 2026, PRF Technologies announced that GridFeed, its AI-driven energy intelligence and optimization platform, is targeting AI and hyperscale data centers as a strategic growth market amid surging global power demand. Citing Interna...
PRF Technologies Spins Out GridFeed Unit to Drive AI Renewable Energy Trading Partnerships
Sep 9, 2026
PRF Technologies Ltd., a Tel Aviv-based company listed on Nasdaq, straddles healthcare and sustainable energy through reformulated pain-management drugs and AI-powered energy optimization platforms. Its pharma portfolio includes candidates like Oc...
PRF Technologies Posts Wider First-Half 2026 Loss but Bolsters Cash and Equity
Sep 3, 2026
On September 3, 2026, PRF Technologies reported unaudited financial results for the six months ended June 30, 2026, highlighting a modest $14,000 in revenue and an operating loss of $2.5 million. The company’s net loss before tax widened to ...
PRF Technologies Strengthens Capital Base and Advances Biotech and AI Energy Platforms
Jul 27, 2026
PRF Technologies Ltd., a Nasdaq-listed company focused on reformulating established therapeutics and developing AI-driven energy optimization tools, operates through a biotechnology platform centered on extended-release drug delivery and a renewab...
PRF Technologies to Present AI-Powered GridFeed Platform at Energy Trading Week Europe 2026
Jul 21, 2026
PRF Technologies’ DeepSolar unit is preparing to showcase its GridFeed platform at Energy Trading Week Europe 2026, which will be held September 24–25, 2026, at London’s Business Design Centre. Announced on July 21, 2026, the par...
PRF Technologies Validates DeepSolar Predict AI Platform Ahead of Commercial Launch
Jul 8, 2026
On July 8, 2026, PRF Technologies announced that its DeepSolar unit has completed an initial validation phase for DeepSolar Predict, an AI-driven revenue optimization platform for renewable energy operators. The validation marks a key milestone as...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.